Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Attorney Docket Number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/565,068 Filing Date July 13, 2006 First Named Inventor Parry John Guilford Art Unit 1643 Examiner Name Alana Harris PEBL-01006US1

(Use as many sheets as necessary)

Substitute for form 1449/PTO

Sheet 1

U. S. PATENT DOCUMENTS Examiner Cite Document Number Publication Date Name of Patentee or Pages, Columns, Lines, Where MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Figures Appear Number-Kind Code^{2 (if known)} US-US US-US-US-US-US-บร-US-US-US-US-US-

		FORE	IGN PATENT DOCL	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Publics Dat	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
			MM-DD-YYYY			T'
	1	WO 2001/94629	12-13-2001	Young		
	2	WO 1998/41864	09-24-1998	Ristimaki		

Examiner	Date	
Signature	Considered	
-		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the region of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. § Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND**TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PEBL-01006US1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/565,068 INFORMATION DISCLOSURE Filing Date July 13, 2006 STATEMENT BY APPLICANT First Named Inventor Parry John Guilford Art Unit 1643 (Use as many sheets as necessary) Examiner Name Alana Harris

Attorney Docket Number

Sheet

3

Гинтейн с	0:4-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	European Examination Report dated Oct. 6, 2010 in Application No. 04778461.6 - 1222 / 1649064	
	2	DEZWART, LOECKIE, L., Biomarkers of free radical damage applications in experimental animals and in humans, Free Radical Biology & Medicine, Vol. 26, Nos.1/2, pp. 202-226,1999	
	3	SALMELA, MT, Parallel expression of macrophage metalloelastase (MMP-12) in duedenal and skin lesions and patients with dermatitis herpetiformis, GUT online, Gut2001;48;496-502	
	3	13 April 2008	
	4	FINLAY, MARTIN BJ, Prostate Cancer Prostatic Dis.2004 Mar 9, PubMed, Louisiana University Health Sciences Center, New Orleans, LA.	
	5	Japanese Office Action translation.	
	6	YOSHIKAWA, TAKAKI, Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in polasma of patients with gastric cancer, Elsevier, Cancer Letters 151 (2000) 81-86	
	7	RUDLAND, PHILIP S., Prognostic Significance of the Metastasis-associated Protein Osteopontin in Human Breast Cancer, Cancer Research 62, 3417-3427, June 15, 2002	
	8	Taiwanese Office Action, translation	
	9	BUCKHAULTS, PHILLIP, Secreted and cell surface genes expressed in benign and malignant colorectal tumors, Cancer Research 61, 6996-7001, October 1, 2001	

Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known
Application Number** Substitute for form 1449/PTQ Filing Date INFORMATION DISCLOSURE July 13, 2006 STATEMENT BY APPLICANT First Named Inventor Parry John Guilford Art Unit 1643 (Use as many sheets as necessary) **Examiner Name** Alana Harris Attorney Docket Number Sheet 3 PEBL-01006US1 of

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	10	HOTTE, SEBASTIAN J., Plasma Osteopontin, 2002, American Cancer Society			
	11	KIM, JAE-HOON, Osteopontin as a potential diagnostic biomarker for ovarian cancer, JAMA, American Medical Association, April 3, 2002, Vol. 287, No. 13. 1671-1682.			
	·				

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

considered. Include copy of this form with rext communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.